Press release content from Business Wire. The AP news staff was not involved in its creation.
Athersys Announces CEO Transition
CLEVELAND, Ohio (BUSINESS WIRE) Feb 16, 2021
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer. Dr. Ismail Kola, Lead Director of the Athersys Board, has been appointed Chairman of the Board.
The Company’s Board is commencing a comprehensive search process to identify a permanent CEO. The Board intends to identify and select a CEO who can guide Athersys in the commercial stage.
citybizlist : New York : Aquestive Therapeutics Appoint Julie Krop, M D , and Marco Taglietti, M D , To Board
citybizlist.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citybizlist.com Daily Mail and Mail on Sunday newspapers.
Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors
February 09, 2021 07:30 ET | Source: Aquestive Therapeutics, Inc. Aquestive Therapeutics, Inc. Warren, New Jersey, UNITED STATES
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board
Share this article
Share this article
SAN DIEGO, Calif. and SHANGHAI, Feb. 2, 2021 /PRNewswire/ Inmagene Biopharmaceuticals ( Inmagene ), a leading biotech company focused on immunology-related therapeutic areas, today announced the launch of its wholly-owned subsidiary in San Diego. Jean-Louis Saillot, MD has joined the company as Chief Development Officer (CDO) to oversee its global product development and clinical trial activities. Inmagene U.S. is integral to our global innovation platform, said Dr. Jonathan Wang, Inmagene s Chairman and CEO. Dr. s Saillot has brought us over three decades of clinical research and development experience from multinational pharmaceutical companies, such as BMS/Celgene, Merck/Schering-Plough, and SmithKline Beecham. His experience in leading multiple successful NDAs/MMAs will greatly boost Inmagene s global drug development capabilities, and enable us to introduce well-needed medicines to the large patient populations in Asia.